Aimmune Therapeutics (NASDAQ:AIMT) Shares Up 5.9%

Aimmune Therapeutics Inc (NASDAQ:AIMT)’s share price shot up 5.9% on Tuesday . The stock traded as high as $31.90 and last traded at $31.88, 1,081,036 shares traded hands during trading. An increase of 51% from the average session volume of 716,060 shares. The stock had previously closed at $30.09.

Several research firms have recently weighed in on AIMT. Stifel Nicolaus upgraded shares of Aimmune Therapeutics to a “positive” rating in a research report on Monday, September 16th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. BidaskClub upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday. Piper Jaffray Companies set a $60.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, Goldman Sachs Group set a $27.00 price objective on shares of Aimmune Therapeutics and gave the company a “hold” rating in a research report on Friday, October 25th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $43.11.

The company’s 50-day moving average price is $27.89 and its two-hundred day moving average price is $22.52. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.64 and a current ratio of 4.64. The stock has a market cap of $1.86 billion, a PE ratio of -8.69 and a beta of -0.03.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) EPS for the quarter, hitting analysts’ consensus estimates of ($1.03). During the same quarter in the previous year, the firm posted ($0.89) earnings per share. Equities research analysts forecast that Aimmune Therapeutics Inc will post -3.97 earnings per share for the current fiscal year.

In other Aimmune Therapeutics news, CFO Eric Bjerkholt bought 1,550 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were bought at an average price of $22.57 per share, for a total transaction of $34,983.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.75% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of AIMT. Marshall Wace North America L.P. purchased a new position in Aimmune Therapeutics in the 1st quarter worth $32,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Aimmune Therapeutics in the 2nd quarter worth $212,000. Janney Montgomery Scott LLC purchased a new position in Aimmune Therapeutics in the 2nd quarter worth $296,000. Aperio Group LLC purchased a new position in Aimmune Therapeutics in the 2nd quarter worth $76,000. Finally, Wedbush Securities Inc. raised its position in Aimmune Therapeutics by 99.4% in the 2nd quarter. Wedbush Securities Inc. now owns 22,057 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 10,997 shares during the period. Institutional investors own 82.31% of the company’s stock.

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: Are sell-side analysts objective?

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.